Q-omics provides the consensus-scored GOLGA6L4 profile across patient tissues and cancer cell-line models. GOLGA6L4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GOLGA6L4 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, GOLGA6L4 RNA expression shows 15,342 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, BRCA, and THYM as cancer lineages where GOLGA6L4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6L4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6L4 survival associations across molecular data types. GOLGA6L4 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6L4 RNA expression–survival associations across cancer types. High GOLGA6L4 expression shows unfavorable associations in LUAD, KIRC, LUSC, STAD and CHOL, but favorable associations in PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for GOLGA6L4 RNA expression.
This table summarizes GOLGA6L4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6L4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6L4 shows lower tumor expression in BRCA, UCEC, BLCA and THCA and higher tumor expression in KICH and CHOL. The BRCA box plot shows higher GOLGA6L4 RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p < 0.001).
This table shows molecular features associated with GOLGA6L4 in patient tissues and cancer cell lines. In patient samples, GOLGA6L4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA6L4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
